| View |
|
BR-1121
|
Trastuzumab
|
Herceptin
|
600 mg/5 mL (120 mg/mL)
|
Solution for Injection (SC)
|
Prescription Drug (Rx)
|
6 mL (Net content: 5 mL) Type I clear glass vial with butyl rubber stopper laminated with a fluoro-resin (Box of 1's
|
Antineoplastic Agents [HER2 (Human Epidermal Growth
Factor Receptor 2) Inhibitors]
|
F. Hoffman-La Roche AG
|
Switzerland
|
N/A
|
|
|
Initial (Variation)
|
26 February 2025
|
26 February 2030
|
| View |
|
BR-1122
|
Rituximab
|
Mabthera
|
1400 mg/11.7 mL
|
Solution for Injection (SC)
|
Prescription Drug (RX)
|
Type I USP/Ph.Eur. colourless glass vial sealed with butyl rubber stopper laminated with fluororesin film and crimped with an aluminum overseal fitted with a plastic flip-off disk x 15 mL (Box of 1's)
|
Antineoplastic Agents
|
F. Hoffman-La Roche AG.
|
Switzerland
|
N/A
|
|
|
Initial (Variation)
|
26 February 2025
|
26 February 2030
|
| View |
|
BR-1123
|
Obinutuzumab
|
Gazyva
|
1 g/40 mL (25mg/mL)
|
Concentrate For Solution For Infusion (IV)
|
Prescription Drug (RX)
|
Type I Borosilicate glass vial with fluoro resign stopper and aluminum overseal with plastic flip-off disk x 40mL (Box of 1's)
|
-
|
Roche Diagnostics GmbH
|
Germany
|
N/A
|
Roche (Philippines) Inc.
|
Roche (Philippines) Inc.
|
Initial (Variation)
|
12 August 2022
|
12 August 2027
|
| View |
BR-1125_PI_01.pdf
|
BR-1125
|
Quadrivalent Seasonal Influenza Vaccine (Split Virion,
Inactivated) Southern Hemisphere 2025 Strain
|
Fluarix Tetra
|
0.5 mL
|
Suspension for Injection (IM) [See formulation on the reverse side]
|
Prescription Drug (RX)
|
0.5 mL in 1.25 mL Type I pre-filled glass syringe with FM30
30 styrene butadiene rubber tip cap. Polypropylene rigid cap, Luer lock adaptor and 2 separate needles (25G 5/8" and 25G 1") in a plastic tray (Box of 1's)
|
Vaccines
|
GlaxoSmithKline
Biologicals NL Der
Beecham Pharma GmbH & Co. KG
|
Germany
|
N/A
|
GlaxoSmithKline Philippines, Inc.
|
GlaxoSmithKline Philippines, Inc.
|
Monitored Release (Variation)
|
30 May 2025
|
19 March 2026
|
| View |
|
BR-1126
|
Secukinumab
|
Cosentyx
|
150 mg/mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
1 mL Type I pre-filled glass syringe with grey
bromobutyl rubber plunger stopper, stainless steel 276 12" needle and rubber needle shield, assembled in UltraSafe PassiveTM Needle Guard X100L (Box of l's and 2's)
|
Interleukin Inhibitors
|
Novartis Pharma Stein AG
|
Switzerland
|
N/A
|
Novartis Healthcare Philippines, Inc.
|
Novartis Healthcare Philippines, Inc.
|
Initial (from Monitored Release)
|
12 April 2022
|
06 January 2026
|
| View |
|
BR-1127
|
Secukinumab
|
Scapho
|
150 mg
|
Powder For Solution For Injection (SC)
|
Prescription Drug (RX)
|
6 mL Type I colourless glass vial with grey chlorobutyl rubber stopper and aluminum crimp with white flip-off cap (Box of 1's)
|
Interleukin Inhibitors
|
Novartis Pharma Stein AG, Pharmaceutical
|
Switzerland
|
N/A
|
Sandoz Philippines Corporation
|
Sandoz Philippines Corporation
|
Initial (from Monitored Release)
|
07 April 2022
|
14 January 2026
|
| View |
BR-1130_PI_01.pdf
|
BR-1130
|
Secukinumab
|
Scapho
|
150 mg/mL
|
Solution for Injection (SC)
|
Prescription Drug (RX)
|
1 mL Type 1 pre-filled glass syringe with grey bromobutyl rubber plunger stopper, stainless steel 27G 1⁄2" needle and rubber needle shield, assembled in an autoinjector pen with transparent window (Senso Ready pen) (Box of 1's)
|
Interleukin Inhibitors
|
Novartis Pharma Stein AG, Pharmaceutical
Schweiz Steriles
|
Switzerland
|
N/A
|
Novartis Healthcare Philippines, Inc.
|
Novartis Healthcare Philippines, Inc.
|
Initial (Variation)
|
02 September 2025
|
02 September 2030
|
| View |
BR-1133_PI_01.pdf
|
BR-1133
|
Pneumococcal Conjugate Vaccine, 13-Valent
(adsorbed) [See formulation on reverse side]
|
Prevenar 13
|
0.5 mL
|
Suspension For Injection (IM)
|
Prescription Drug (RX)
|
Single Dose : 0.5 mL suspension for injection in Becton-Dickinson (BD) Hypak® SCFR Luer-Lok® syringes or Schott SyriQ Luer-Lok® Round Flange pre-filled syringe (Type I Glasss) with separate 25G needle in a Box
|
-
|
Pfizer Ireland Pharmaceuticals
|
Ireland
|
|
Pfizer, Inc.
|
Pfizer, Inc.
|
-
|
10 September 2021
|
21 January 2026
|
| View |
|
BR-1135
|
Chorionic Gonadotrophin
|
Chorapur
|
5000 IU
|
Powder for Injection (IM)
|
Prescription Drug (RX)
|
Type I Glass Vial + 1 mL Type I Glass Ampoule (Diluent: 0.9% Sodium chloride) (Box of 3's)
|
-
|
Ferring GmbH
|
Germany
|
|
Metro Drug, Inc.
|
Metro Drug, Inc.
|
-
|
08 March 2021
|
09 February 2026
|
| View |
BR-1138_PI_02.pdf
|
BR-1138
|
Pembrolizumab
|
Keytruda
|
100 mg/4 mL (25 mg/mL)
|
Solution for Injection (IV
Infusion)
|
Prescription Drug (RX)
|
10 mL Type I glass vial, with a grey chlorobutyl stopper and an aluminum seal with a dark blue flip-off cap (Box of 1's) 10 mL Type I glass vial with a grey chlorobutyl stopper and an aluminum seal with a dark blue flip-off cap (Box of 1's) [For Government Tender (DOH-Pack-Cancer Assistance Fund)]
|
Monoclonal Antibodies
|
MSD International GmbH T/A MSD Ireland (Carlow)
|
Ireland
|
|
Merck Sharp & Dohme (I.A.) LLC
|
N/A
|
Initial (Variation)
|
31 March 2025
|
31 March 2030
|
| View |
|
BR-1141
|
Rituximab
|
Mabthera
|
10 mg/ mL
|
Concentrate For Solution For Infusion (IV)
|
Prescription Drug (RX)
|
10 mL and 50 mL USP Type I Colorless Glass Vial (Box of 1's)
|
-
|
Roche Diagnostic GmbH
|
Germany
|
|
Roche (Philippines), Inc.
|
Zuellig Pharma Corporation
|
-
|
08 March 2021
|
24 November 2025
|
| View |
|
BR-1148
|
Combined Diphtheria, Tetanus, Acellular Pertussis Vaccine, Adsorbed
|
Boostrix
|
Formulation: 1 dose (0.5 mL) contains:
Diphtheria toxoid*-Not less than 2 IU (2.5Lf) Tetanus toxoid*-Not less than 20 IU (5Lf) Pertussis toxoid (PT)*-8mcg Filamentous Hemagglutinin (FHA)*-8mcg Pertactin-2.5mcg *adsorbed on Aluminum hydroxide, hydrated (Al(OH)3)-300 mcg Al3 and Aluminum phosphate (AlPO4)-200 mcg A13+
|
Suspension For Injection (I.M.)
|
Prescription Drug (RX)
|
0.5 mL Suspension in Type I Glass Vial with Gray Butyl Rubber Stopper and Flip-off Cap (Box of 10's)
|
Vaccine
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
N/A
|
GlaxoSmithKline Philippines, Inc.
|
N/A
|
Renewal
|
27 April 2021
|
03 June 2026
|
| View |
|
BR-1152
|
Siltuximab
|
Sylvant
|
100 mg
|
Powder For Concentrate For Solution For Infusion
|
Prescription Drug (RX)
|
8 mL Type I clear glass vial closed with a
fluoropolymer coated 20 mm lyophilization-type stopper and a 20 mm aluminum seal with a flip-off button (Box of l's)
|
-
|
Cilag AG
|
Switzerland
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Initial
|
19 October 2021
|
04 August 2026
|
| View |
|
BR-1153
|
Siltuximab
|
Sylvant
|
400 mg
|
Powder For Concentrate For Solution For Infusion
|
Prescription Drug (RX)
|
30 mL Type I clear glass vial closed with a
fluoropolymer coated 20 mm lyophilization-type stopper and a 20 mm aluminum seal with a flip-off button (Box of l's)
|
-
|
Cilag AG
|
Switzerland
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Initial
|
16 November 2021
|
04 August 2026
|
| View |
|
BR-1154
|
Insulin glargine
|
Basagine
|
100 Units/mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
1-PVC Tray containing 3 mL Solution in 5 mL USP Type I Clear Glass Vial with Cream Color Rubber Stopper and Aluminum Seal with Purple Color Flip-off Cap (Box of 1's)
|
Insulins and Analogues
|
Getz Pharma Pvt. Ltd.
|
Pakistan
|
|
Getz Pharma Phils., Inc.
|
|
Renewal
|
04 August 2025
|
03 June 2031
|
| View |
|
BR-1155
|
Human Normal Immunoglobulin
|
Octagam 10%
|
100mg/mL (10% w/v)
|
Solution for IV Infusion
|
Prescription Drug (RX)
|
Type II Glass Bottle with Bromobutyl Rubber Stopper
sealed with Aluminum Flip-off Cap (20 mL solution in 30 mL; 50 mL Solution in 70 mL; 100 mL; 200 mL Solution in 250 mL) (Box of 1's)
|
Immunoglobulin
|
Octapharma Pharmazeutika Produktionsges.m.b.H
|
Austria
|
N/A
|
Medlink Marketing
|
Medlink Marketing
|
Renewal
|
25 March 2022
|
07 June 2026
|
| View |
|
BR-1156
|
Human Normal Immunoglobulin
|
Octagam 5%
|
50mg/mL (5% w/v)
|
Solution for IV Infusion
|
Prescription Drug (RX)
|
Type II Glass Bottle with Bromobutyl Rubber Stopper
sealed with Aluminum flip-off cap (20 mL Solution in 30 mL; 50 mL solution in 70 mL; 100 mL; 200 mL Solution in 250 mL) (Box of 1's)
|
-
|
Octapharma Pharmazeutika Produktionsges.m.b.H
|
Austria
|
N/A
|
Medlink Marketing
|
Medlink Marketing
|
-
|
25 March 2022
|
07 June 2026
|
| View |
|
BR-1157
|
Human Albumin
|
Albunorm 25%
|
250 g/L (25% w/v)
|
Solution for IV Infusion
|
Prescription Drug (RX)
|
Type II infusion glass bottle with bromobutyl rubber
stopper x 50 mL and 100 mL (Box of l's)
|
-
|
Octapharma
|
France
|
|
Medlink Marketing
|
Medlink Marketing
|
-
|
20 January 2022
|
06 June 2026
|
| View |
|
BR-1165
|
Human Albumin
|
Albunorm 20%
|
200 g/L (20% w/v)
|
Solution for IV Infusion
|
Prescription Drug (Rx)
|
50 mL of solution in infusion bottle (type II glass) with bromobutyl rubber stopper (Box of 1's); 100 mL of solution in infusion bottle (type II glass) with bromobutyl rubber stopper (Box of 1's)
|
Blood substitutes and plasma protein fractions
|
Octapharma Produktionsgesellschaft Deutschland GmbH
|
Germany
|
Repacker: Octapharma Dessau GmbH
|
Medlink Marketing
|
Medlink Marketing
|
Automatic Renewal
|
26 October 2021
|
26 July 2026
|
| View |
|
BR-1168
|
Human Papillomavirus 9-Valent Vaccine (Recombinant, Adsorbed)
|
Gardasil 9
|
Formulation: Each dose (0.5 mL) contains: Human Papillomavirus Type 6 L1 protein-30mcg Human Papillomavirus Type 11 L1 protein-40mcg Human Papillomavirus Type 16 Ll protein-60mcg Human Papillomavirus Type 18 Li protein-40mcg Human Papillomavirus Type 31 Ll protein-20 mcg Human Papillomavirus Type 33 L1 protein-20mcg Human Papillomavirus Type 45 Ll protein-20mcg Human Papillomavirus Type 52 L1 protein-20mcg Human Papillomavirus Type 58 LI protein-20mcg
Adsorbed on amorphous aluminum hydroxide sulphate adjuvant -500 mcg Al
|
Suspension for Injection (IM)
|
Prescription Drug (RX)
|
0.5 mL in 1.5 mL Type I pre-filled glass syringe with bromobutyl plunger stopper and tip cap + 2 sterile
needles (236 x 1" and 256 x 1") [Box of 1's]
|
-
|
Merck Sharp & Dohme Corp.
|
United States of America
|
N/A
|
Merck Sharp & Dohme (I.A.) LLC
|
N/A
|
Initial
|
30 March 2022
|
19 August 2026
|